TB Discovery Research Infectious Disease Research Institute Seattle

United States

TB Discovery Research Infectious Disease Research Institute Seattle

United States
SEARCH FILTERS
Time filter
Source Type

Russo F.,Uppsala University | Gising J.,Uppsala University | Akerbladh L.,Uppsala University | Roos A.K.,Uppsala University | And 10 more authors.
ChemistryOpen | Year: 2015

This is the first report of 5-styryl-oxathiazol-2-ones as inhibitors of the Mycobacterium tuberculosis (Mtb) proteasome. As part of the study, the structure-activity relationship of oxathiazolones as Mtb proteasome inhibitors has been investigated. Furthermore, the prepared compounds displayed a good selectivity profile for Mtb compared to the human proteasome. The 5-styryl-oxathiazol-2-one inhibitors identified showed little activity against replicating Mtb, but were rapidly bactericidal against nonreplicating bacteria. (E)-5-(4-Chlorostyryl)-1,3,4-oxathiazol-2-one) was most effective, reducing the colony-forming units (CFU)/mL below the detection limit in only seven days at all concentrations tested. The results suggest that this new class of Mtb proteasome inhibitors has the potential to be further developed into novel antitubercular agents for synergistic combination therapies with existing drugs. © 2015 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA..

Loading TB Discovery Research Infectious Disease Research Institute Seattle collaborators
Loading TB Discovery Research Infectious Disease Research Institute Seattle collaborators